BR112017008914A2 - método para tratar câncer, composição e uso da composição - Google Patents

método para tratar câncer, composição e uso da composição

Info

Publication number
BR112017008914A2
BR112017008914A2 BR112017008914A BR112017008914A BR112017008914A2 BR 112017008914 A2 BR112017008914 A2 BR 112017008914A2 BR 112017008914 A BR112017008914 A BR 112017008914A BR 112017008914 A BR112017008914 A BR 112017008914A BR 112017008914 A2 BR112017008914 A2 BR 112017008914A2
Authority
BR
Brazil
Prior art keywords
makeup
treating cancer
csf1r
colony
antibodies
Prior art date
Application number
BR112017008914A
Other languages
English (en)
Inventor
Wong Brian
Hambleton Julie
Sikorski Robert
Masteller Emma
Hestir Kevin
Bellovin David
E. Lewis Katherie
Original Assignee
Five Prime Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics, Inc. filed Critical Five Prime Therapeutics, Inc.
Publication of BR112017008914A2 publication Critical patent/BR112017008914A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

são fornecidos métodos para tratar câncer com anticorpos que se ligam ao receptor de fator 1 estimulador de colônias (csf1r) em combinação com inibidores de pd-1/pd-l1.
BR112017008914A 2014-10-29 2015-10-28 método para tratar câncer, composição e uso da composição BR112017008914A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462072035P 2014-10-29 2014-10-29
US201562157368P 2015-05-05 2015-05-05
US201562192025P 2015-07-13 2015-07-13
PCT/US2015/057781 WO2016069727A1 (en) 2014-10-29 2015-10-28 Combination therapy for cancer

Publications (1)

Publication Number Publication Date
BR112017008914A2 true BR112017008914A2 (pt) 2018-01-16

Family

ID=54695820

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008914A BR112017008914A2 (pt) 2014-10-29 2015-10-28 método para tratar câncer, composição e uso da composição

Country Status (25)

Country Link
US (5) US9765147B2 (pt)
EP (2) EP3212670B1 (pt)
JP (3) JP6920989B2 (pt)
KR (1) KR102636539B1 (pt)
CN (1) CN107567336B (pt)
AU (1) AU2015339306B2 (pt)
BR (1) BR112017008914A2 (pt)
CA (1) CA2963147A1 (pt)
CY (1) CY1123957T1 (pt)
DK (1) DK3212670T3 (pt)
EA (1) EA036261B1 (pt)
ES (1) ES2851390T3 (pt)
HR (1) HRP20210440T1 (pt)
HU (1) HUE054012T2 (pt)
IL (1) IL251464B2 (pt)
LT (1) LT3212670T (pt)
MX (1) MX2017005553A (pt)
PL (1) PL3212670T3 (pt)
PT (1) PT3212670T (pt)
RS (1) RS61602B1 (pt)
SG (1) SG11201702723VA (pt)
SI (1) SI3212670T1 (pt)
TW (1) TWI711463B (pt)
WO (1) WO2016069727A1 (pt)
ZA (1) ZA201702382B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130302322A1 (en) * 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
RS59480B1 (sr) 2013-12-12 2019-12-31 Shanghai hengrui pharmaceutical co ltd Pd-1 antitelo, njegov fragment koji se vezuje na antigen, i njegova medicinska primena
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3971209A1 (en) 2014-02-04 2022-03-23 Pfizer Inc. Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
KR20170016501A (ko) * 2014-06-23 2017-02-13 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법
US9993551B2 (en) 2014-09-13 2018-06-12 Novartis Ag Combination therapies of EGFR inhibitors
KR102636539B1 (ko) 2014-10-29 2024-02-13 파이브 프라임 테라퓨틱스, 인크. 암에 대한 조합 요법
SG11201703925VA (en) * 2014-12-02 2017-06-29 Celgene Corp Combination therapies
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
WO2016137985A1 (en) * 2015-02-26 2016-09-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
SG11201707383PA (en) 2015-03-13 2017-10-30 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
EA039951B1 (ru) * 2015-05-27 2022-03-31 Юсб Биофарма Спрл Ингибитор активности csf-1r, предназначенный для лечения или профилактики эпилепсии или болезни паркинсона, и фармацевтическая композиция на его основе
MX2017016324A (es) 2015-06-16 2018-03-02 Merck Patent Gmbh Tratamientos de combinacion de antagonista de ligando 1 de muerte programada (pd-l1).
KR20180040138A (ko) 2015-07-13 2018-04-19 싸이톰스 테라퓨틱스, 인크. 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
CR20180318A (es) 2015-12-14 2018-09-19 Macrogenics Inc Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
EP3463454A1 (en) 2016-06-03 2019-04-10 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
RU2725950C1 (ru) 2016-08-05 2020-07-07 И-Байолоджикс Инк. Антитела против белка-1 запрограммированной клеточной смерти (pd-1) и их применение
WO2018036852A1 (en) 2016-08-25 2018-03-01 F. Hoffmann-La Roche Ag Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
CN110191721A (zh) 2016-09-26 2019-08-30 集合集团控股公司 有淋巴***失调的受试者中癌症的评估与治疗方法
AU2017339856A1 (en) 2016-10-06 2019-05-23 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
US20190292246A1 (en) 2016-11-03 2019-09-26 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia imhibitor
JP7304287B2 (ja) * 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
WO2018181425A1 (ja) * 2017-03-29 2018-10-04 塩野義製薬株式会社 癌治療用医薬組成物
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
SG11202001606XA (en) * 2017-09-13 2020-03-30 Five Prime Therapeutics Inc Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
JP2021503478A (ja) * 2017-11-16 2021-02-12 ノバルティス アーゲー 組み合わせ治療
PT3720879T (pt) * 2017-12-05 2022-07-13 Progastrine Et Cancers S A R L Terapia de combinação entre anticorpo anti-progastrina e imunoterapia para tratar o cancro
WO2019113464A1 (en) * 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2019139583A1 (en) * 2018-01-10 2019-07-18 Lee Patrice A Methods and combination therapy to treat cancer
WO2019173361A2 (en) * 2018-03-05 2019-09-12 The Schepens Eye Research Institute, Inc. A therapy for glaucoma and optic neuropathy by targeting colony stimulating factors
CN108610422B (zh) * 2018-03-29 2019-05-28 中国人民解放军军事科学院军事医学研究院 抑制pd-1/pd-l1信号通路的结合分子
CN111971306A (zh) * 2018-03-30 2020-11-20 百时美施贵宝公司 ***的方法
JP7407452B2 (ja) * 2018-07-31 2024-01-04 国立大学法人北海道大学 がんの治療及び／又は予防のための医薬
WO2020058372A1 (en) * 2018-09-19 2020-03-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
WO2020243338A1 (en) * 2019-05-31 2020-12-03 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
CN114907267A (zh) * 2021-02-08 2022-08-16 中国科学院上海药物研究所 用于抗肿瘤的药物组合

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU2728588A (en) 1987-10-23 1989-05-23 Genetics Institute Inc. Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1993025687A1 (en) 1992-06-09 1993-12-23 Chiron Corporation Crystallization of m-csf
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999029345A1 (en) 1997-12-05 1999-06-17 La Jolla Institute For Experimental Medicine Inhibition of tumor growth by macrophage intervention
AU6366999A (en) 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
US6808710B1 (en) 1999-08-23 2004-10-26 Genetics Institute, Inc. Downmodulating an immune response with multivalent antibodies to PD-1
AU783063B2 (en) 1999-10-28 2005-09-22 Seyedhossein Aharinejad Use of CSF-1 inhibitors
WO2001034177A2 (en) 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US6773895B2 (en) 2000-09-01 2004-08-10 Boehringer Ingelheim Pharma Kg Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
US7247618B2 (en) 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CN1787837A (zh) 2002-11-15 2006-06-14 希龙公司 防止和治疗癌转移以及与癌转移相关的骨质损失的方法
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
US7807389B2 (en) 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
WO2004113304A1 (en) 2003-05-22 2004-12-29 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
SI1678314T1 (sl) 2003-10-22 2013-01-31 Keck Graduate Institute Metode za sintetiziranje heteromultimernih polipeptidov pri kvasovkah s strategijo razmnoĺ˝evanja haploidnih celic
GB0325836D0 (en) 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
JP2007524671A (ja) 2004-01-21 2007-08-30 カイロン コーポレイション Ｍ−ｃｓｆムテインおよびその使用
EP1745073A2 (en) 2004-05-14 2007-01-24 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
ATE540973T1 (de) 2004-07-22 2012-01-15 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
JP2008528033A (ja) 2005-01-27 2008-07-31 ファイブ プライム セラピューティクス， インコーポレイテッド ポリペプチドの分泌を検出するためのリーダー配列およびその産生のための方法
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
LT2439273T (lt) 2005-05-09 2019-05-10 Ono Pharmaceutical Co., Ltd. Žmogaus monokloniniai antikūnai prieš programuotos mirties 1(pd-1) baltymą, ir vėžio gydymo būdai, naudojant vien tik anti-pd-1 antikūnus arba derinyje su kitais imunoterapiniais vaistais
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CN101384621A (zh) 2005-11-10 2009-03-11 受体生物公司 产生受体和配体同种型的方法
WO2007075933A2 (en) 2005-12-21 2007-07-05 Cell Signaling Technology, Inc. Translocation and mutant csf1r kinase in human leukemia
WO2007120252A2 (en) 2005-12-22 2007-10-25 Novartis Ag Soluble human m-csf receptor and uses thereof
CA2636149A1 (en) 2006-01-05 2007-07-19 Novartis Ag Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
JP2010510219A (ja) 2006-11-17 2010-04-02 バイオジェン・アイデック・エムエイ・インコーポレイテッド アミロイド関連障害を処置するためのコロニー刺激因子の全身投与
WO2008100995A1 (en) 2007-02-14 2008-08-21 Vaccinex, Inc. Humanized anti-cd100 antibodies
WO2008124858A2 (en) 2007-04-11 2008-10-23 F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. Targeted receptor
WO2008150383A1 (en) 2007-05-30 2008-12-11 Albert Einstein College Of Medicine Of Yeshiva University Csf-1r mutants
DK2170959T3 (da) 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
CL2008002444A1 (es) 2007-08-21 2009-09-04 Amgen Inc Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
WO2009058968A2 (en) 2007-10-31 2009-05-07 Janssen Pharmaceutica N.V. Biomarker for assessing response to fms treatment
US20110262425A1 (en) 2007-12-12 2011-10-27 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CN102702358B (zh) 2008-03-14 2016-02-17 天士力创世杰（天津）生物制药有限公司 针对csf-1r的抗体
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
WO2009137378A2 (en) * 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
JP5945096B2 (ja) * 2008-07-04 2016-07-05 小野薬品工業株式会社 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用
NZ591130A (en) 2008-08-25 2012-09-28 Amplimmune Inc Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
WO2010062401A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
SI2376535T1 (sl) 2008-12-09 2017-07-31 F. Hoffmann-La Roche Ag Protitelesa anti-pd-l1 in njihova uporaba za izboljšanje funkcije celic t
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
CA2789076C (en) 2010-03-05 2017-11-21 F. Hoffmann-La Roche Ag Antibodies against human colony stimulating factor-1 receptor and uses thereof
BR112012022046A2 (pt) 2010-03-05 2017-02-14 F Hoffamann-La Roche Ag ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
US8206715B2 (en) * 2010-05-04 2012-06-26 Five Prime Therapeutics, Inc. Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
EP2910572B1 (en) * 2010-11-11 2017-09-06 Versitech Limited Soluble pd-1 variants, fusion constructs, and uses thereof
TW201307845A (zh) 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
LT2699264T (lt) 2011-04-20 2018-07-10 Medimmune, Llc Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1
CA2852800A1 (en) 2011-10-21 2013-04-25 Inserm (Institut National De La Sante Et De La Recherche Medicale) A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system
CA2851771C (en) 2011-10-21 2018-09-11 Transgene Sa Modulation of macrophage activation
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
EP2847220A1 (en) 2012-05-11 2015-03-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
AU2013308635A1 (en) 2012-08-31 2015-03-12 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
AR097584A1 (es) * 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
KR102636539B1 (ko) 2014-10-29 2024-02-13 파이브 프라임 테라퓨틱스, 인크. 암에 대한 조합 요법
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
AU2017339517B2 (en) 2016-10-06 2024-03-14 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
JP2020527351A (ja) 2017-07-21 2020-09-10 ジェネンテック， インコーポレイテッド がんの治療法及び診断法

Also Published As

Publication number Publication date
AU2015339306A1 (en) 2017-04-20
US20160152715A1 (en) 2016-06-02
CN107567336A (zh) 2018-01-09
KR20170074962A (ko) 2017-06-30
JP6920989B2 (ja) 2021-08-18
JP2017533912A (ja) 2017-11-16
US10221244B2 (en) 2019-03-05
HUE054012T2 (hu) 2021-08-30
SG11201702723VA (en) 2017-05-30
US20180094067A1 (en) 2018-04-05
IL251464B (en) 2022-11-01
EP3835323A1 (en) 2021-06-16
AU2015339306B2 (en) 2021-07-22
EA036261B1 (ru) 2020-10-20
CY1123957T1 (el) 2022-05-27
US10618967B2 (en) 2020-04-14
US20230212299A1 (en) 2023-07-06
PL3212670T3 (pl) 2021-06-14
HRP20210440T1 (hr) 2021-04-30
RS61602B1 (sr) 2021-04-29
EP3212670B1 (en) 2020-12-23
LT3212670T (lt) 2021-02-10
DK3212670T3 (da) 2021-03-22
US20200299392A1 (en) 2020-09-24
KR102636539B1 (ko) 2024-02-13
CN107567336B (zh) 2021-12-31
US9765147B2 (en) 2017-09-19
EA201790926A1 (ru) 2017-09-29
CA2963147A1 (en) 2016-05-06
US11566076B2 (en) 2023-01-31
IL251464B2 (en) 2023-03-01
WO2016069727A1 (en) 2016-05-06
JP2023052067A (ja) 2023-04-11
SI3212670T1 (sl) 2021-03-31
IL251464A0 (en) 2017-05-29
EP3212670A1 (en) 2017-09-06
US20190202921A1 (en) 2019-07-04
PT3212670T (pt) 2021-02-15
TWI711463B (zh) 2020-12-01
JP2020186243A (ja) 2020-11-19
TW201628653A (zh) 2016-08-16
ZA201702382B (en) 2020-07-29
MX2017005553A (es) 2017-07-04
ES2851390T3 (es) 2021-09-06

Similar Documents

Publication Publication Date Title
BR112017008914A2 (pt) método para tratar câncer, composição e uso da composição
MY195110A (en) Antibodies to PD-1 and uses Thereof
CL2017002401A1 (es) Anticuerpos contra icos
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
CO2019006485A2 (es) Anticuerpos y metodos de su utilizacion
EP4219559A3 (en) Antibodies for lilrb2
BR112018005164A2 (pt) anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de um indivíduo que tem câncer
BR112017020952A2 (pt) método de tratamento de câncer, composição e uso da composição
PH12020500075A1 (en) Checkpoint inhibitor bispecific antibodies
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
NZ731467A (en) Anti-tim3 antibodies and methods of use
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
AR099465A1 (es) Anticuerpos anti-jagged1 y métodos de uso
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
UY34636A (es) Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
PH12016501422B1 (en) Functionalised benzopyran compounds and use thereof
BR112016015693A2 (pt) método para tratar um câncer de próstata e anticorpo
WO2018009507A8 (en) COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
BR112018012883A2 (pt) novos anticorpos anti-upk1b e métodos de uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]